Human Herpesvirus 6 (HHV-6) Encephalitis Secondary to Chimeric Antigen Receptor (CAR)-T Cell Therapy

Overview

Journal Neurol Sci

Specialty Neurology

Date 2024 Nov 5

PMID 39499455

Authors

Fahang Yi

Ningxiang Qin

Liang Wang

Affiliations

Soon will be listed here.

Abstract

Background: Human herpesvirus (HHV)-6 encephalitis secondary to chimeric antigen receptor (CAR)-T cell therapyis relatively rare in clinical practice and needs to be differentiated from immune effector cell-associatedneurotoxicity syndrome (ICANS).

Methods: We retrospectively reported a case of HHV-6 encephalitis secondary to CAR-T cell therapy.

Results: A male patient from China with diffuse large B-cell lymphoma underwent chimeric CAR-T cell therapy anddeveloped a generalized rash on the 8 day, followed by cognitive changes, memory loss, and disorientation onthe 14 day after CAR-T cell therapy. Initially, ICANS was suspected. A lumbar puncture was performed on the 18 day. The cerebrospinal fluid (CSF) analysis revealed slightly elevated protein levels and a high presence of HHV-6B sequences by mNGS. Brain MRI showed bilateral hippocampal abnormalities. The patient was ultimatelydiagnosed with HHV-6 encephalitis and treated with ganciclovir and dexamethasone. After one week of treatment,follow-up CSF analysis showed a reduction in HHV-6B sequences. The patient was discharged with improvedmemory and orientation.

Conclusion: HHV-6 encephalitis secondary to CAR-T cell therapy may be easily confused with ICANS. Timely andaggressive diagnostic procedures, such as mNGS of CSF and cranial imaging, along with prompt antiviral therapy,are crucial for improving patient outcomes.

References

De Bolle L, Naesens L, De Clercq E . Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev. 2005; 18(1):217-45. PMC: 544175. DOI: 10.1128/CMR.18.1.217-245.2005. View

Clark D . Clinical and laboratory features of human herpesvirus 6 chromosomal integration. Clin Microbiol Infect. 2016; 22(4):333-339. DOI: 10.1016/j.cmi.2015.12.022. View

Kampouri E, Little J, Crocchiolo R, Hill J . Human herpesvirus-6, HHV-8 and parvovirus B19 after allogeneic hematopoietic cell transplant: the lesser-known viral complications. Curr Opin Infect Dis. 2024; 37(4):245-253. DOI: 10.1097/QCO.0000000000001020. View

Yuan S, Chen Y, Liu H . Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma. Ther Adv Hematol. 2024; 15:20406207241237594. PMC: 10935756. DOI: 10.1177/20406207241237594. View

Spanjaart A, van der Valk F, van Rooijen G, Brouwer M, Kersten M . Confused about Confusion. N Engl J Med. 2022; 386(1):80-87. DOI: 10.1056/NEJMcps2114818. View

Grut V, Bistrom M, Salzer J, Stridh P, Jons D, Gustafsson R . Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis. Brain. 2023; 147(1):177-185. PMC: 10766246. DOI: 10.1093/brain/awad374. View

Badrinath A, Bhatta S, Kloc A . Persistent viral infections and their role in heart disease. Front Microbiol. 2022; 13:1030440. PMC: 9730422. DOI: 10.3389/fmicb.2022.1030440. View

Ogata M, Kikuchi H, Satou T, Kawano R, Ikewaki J, Kohno K . Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis. 2005; 193(1):68-79. DOI: 10.1086/498531. View

Batlevi C, Matsuki E, Brentjens R, Younes A . Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2015; 13(1):25-40. PMC: 4916838. DOI: 10.1038/nrclinonc.2015.187. View

10.

Lareau C, Yin Y, Maurer K, Sandor K, Daniel B, Yagnik G . Latent human herpesvirus 6 is reactivated in CAR T cells. Nature. 2023; 623(7987):608-615. PMC: 10999258. DOI: 10.1038/s41586-023-06704-2. View

11.

Sterner R, Sterner R . Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front Immunol. 2022; 13:879608. PMC: 9445841. DOI: 10.3389/fimmu.2022.879608. View

12.

Neelapu S . Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019; 37 Suppl 1:48-52. DOI: 10.1002/hon.2595. View

13.

Yassin A, Al-Mistarehi A, El-Salem K, Momani A, Al Qawasmeh M, Rodriguez R . Clinical, radiological, and electroencephalographic features of HHV-6 encephalitis following hematopoietic stem cell transplantation. Ann Med Surg (Lond). 2020; 60:81-86. PMC: 7585839. DOI: 10.1016/j.amsu.2020.10.022. View

14.

Singh N, Paterson D . Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation. 2000; 69(12):2474-9. DOI: 10.1097/00007890-200006270-00002. View

15.

Bhanushali M, Kranick S, Freeman A, Cuellar-Rodriguez J, Battiwalla M, Gea-Banacloche J . Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation. Neurology. 2013; 80(16):1494-500. PMC: 3662358. DOI: 10.1212/WNL.0b013e31828cf8a2. View

16.

Rubin D, Danish H, Ali A, Li K, LaRose S, Monk A . Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019; 142(5):1334-1348. DOI: 10.1093/brain/awz053. View

17.

Beuchat I, Danish H, Rubin D, Jacobson C, Robertson M, Vaitkevicius H . EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations. Neuro Oncol. 2021; 24(2):313-325. PMC: 8804895. DOI: 10.1093/neuonc/noab174. View

18.

Lapidus A, Anderson M, Harrison S, Dickinson M, Kalincik T, Lasocki A . Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. Leuk Lymphoma. 2022; 63(10):2364-2374. DOI: 10.1080/10428194.2022.2074990. View